Business Wire
01 Oct 2026, 06:55 UTC · 3h ago
Verdict
Headline takes no side. We score ALM +0.50 across one claim — strongly bullish.
+0.50strongly bullish
More positive than 72% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Almirall announced results from the Phase 3b ADlong study showing long-term disease control for up to five years for lebrikizumab in moderate-to-severe atopic dermatitis patients.
Newannounced today at EADV Congress
So whatProven 5-year durability reduces the risk of patient churn, potentially increasing the long-term lifetime value (LTV) per patient starting in 2027.
More positive than 93% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 72% of ticker scores this week
Positive announcement of long-term Phase 3b study results for lebrikizumab.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
39m ago
—
ALM hasn't traded since this ran. Last close $13.16 (Sep 30); the reaction starts at the next open.
ALM chart →
